Johnson & Johnson said it saw "very little impact" from biosimilar competition to Remicade, its treatment for arthritis, ulcerative colitis and Crohn's Disease that is seeing increased competition from the likes of Pfizer (PFE) - Get Report , but noted that its pharma sales dipped specifically due to weakness in the U.S.